A Phase 2b clinical trial involving patients with NASH reported that MSDC-0602K, the potassium salt form of MSDC-0602, led to statistically significant reductions in hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and fasting plasma insulin, indicating enhanced insulin sensitivity and improved glycemic control. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.